Aspirin can reduce the risk for cancer-related mortality and can reduce or prevent the risk for distant metastasis, according to 3 new studies published online by The Lancet and The Lancet Oncology.
Aspirin can reduce the risk for cancer-related mortality and can reduce or prevent the risk for distant metastasis, according to 3 new studies published online by The Lancet and The Lancet Oncology.
Aspirin was shown to reduce the risk for nonvascular death in all trials in The Lancetstudy authored by Peter M. Rothwell, FMedSci, and published online first on March 21.
Researchers in the United Kingdom reviewed 5 large, randomized trials of daily aspirin use versus control for the prevention of vascular events. Of 17,285 participants, 987 had a new solid cancer diagnosed during mean in-trial follow-up for 6.5 years. Those taking daily aspirin had a reduced risk of cancer with distant metastasis for all cancers.
In the study, aspirin also reduced death due to cancer in patients who developed adenocarcinoma, particularly in those without metastasis at diagnosis.
“That aspirin prevents distant metastasis could account for the early reduction in cancer deaths in trials of daily aspirin versus control. This finding suggests that aspirin might help in treatment of some cancers and provides proof of principle for pharmacological intervention, specifically to prevent distant metastasis,” the authors stated.
Rothwell and other researchers also reviewed the short-term effects of daily aspirin on cancer incidence and mortality. Those results also were published by The Lancet online on March 21. The researchers found that allocation to aspirin reduced cancer deaths (562 vs 644 deaths) in 51 randomized trials comparing daily aspirin use with no aspirin use for prevention of vascular events.
In the March 21 online edition of The Lancet Oncology, Rothwell and other researchers also reported evidence for benefits of long-term aspirin use for certain types of cancer. In case-control studies, regular use of aspirin was associated with reduced risk of colorectal cancer.
“Similarly consistent reductions were seen in risks of esophageal, gastric, biliary, and breast cancer,” the researchers stated.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.